• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的重复疫苗接种在异基因干细胞移植受者中引发强大的多功能T细胞反应。
Cancer Cell. 2021 Nov 8;39(11):1448-1449. doi: 10.1016/j.ccell.2021.10.002. Epub 2021 Oct 12.
2
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.多发性骨髓瘤完全接种疫苗患者对SARS-CoV-2的细胞反应各异。
Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19.
3
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.癌症患者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）BNT162b2 mRNA疫苗延迟第二剂的体液免疫和细胞免疫
Cancer Cell. 2021 Nov 8;39(11):1445-1447. doi: 10.1016/j.ccell.2021.10.003. Epub 2021 Oct 12.
4
T-cell and Antibody Response After 2 Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients.比利时肾移植受者队列中两剂BNT162b2疫苗后的T细胞和抗体反应
Transplantation. 2021 Oct 1;105(10):e142-e143. doi: 10.1097/TP.0000000000003892.
5
Very Low Immunization Rate in Kidney Transplant Recipients After One Dose of the BNT162b2 Vaccine: Beware not to Lower the Guard!肾移植受者接种一剂BNT162b2疫苗后免疫率极低：谨防放松警惕！
Transplantation. 2021 Oct 1;105(10):e148-e149. doi: 10.1097/TP.0000000000003818.
6
Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.不同和同源的 COVID-19 mRNA 疫苗接种方案在诱导医护人员的长期刺突特异性细胞免疫方面显示出相似的免疫原性。
Vaccine. 2024 Aug 30;42(21):126132. doi: 10.1016/j.vaccine.2024.07.033. Epub 2024 Jul 20.
7
Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination.异源和同源新冠病毒疫苗接种后长达21个月的体液免疫和细胞免疫激活分析
Front Immunol. 2025 May 2;16:1579163. doi: 10.3389/fimmu.2025.1579163. eCollection 2025.
8
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.维持性透析患者接种 SARS-CoV-2 疫苗后 6 个月的血清学反应。
Clin J Am Soc Nephrol. 2022 Mar;17(3):403-413. doi: 10.2215/CJN.12250921. Epub 2022 Feb 10.
9
Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.心脏和胸部移植受者对两剂 SARS-CoV-2 信使 RNA 疫苗 BNT162b2 的体液和 T 细胞应答较差。
Clin Res Cardiol. 2021 Aug;110(8):1142-1149. doi: 10.1007/s00392-021-01880-5. Epub 2021 Jul 9.
10
SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients.灭活新冠疫苗接种者中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）结构蛋白的特异性T细胞免疫
Cell Mol Immunol. 2021 Aug;18(8):2040-2041. doi: 10.1038/s41423-021-00730-8. Epub 2021 Jul 15.

引用本文的文献

1
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.与mRNA疫苗相比，ChAdOx1-S（AZD1222）疫苗接种后造血细胞移植受者体内的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中和抗体反应保留得更多。
Br J Haematol. 2024 Dec;205(6):2206-2218. doi: 10.1111/bjh.19874. Epub 2024 Nov 17.
2
COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases.肺移植受者中的 COVID-19：10 例近期病例报告。
Viruses. 2024 Apr 29;16(5):709. doi: 10.3390/v16050709.
3
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy.通过基于合成双抗原MVA的COVID-19疫苗COH04S1刺激造血细胞移植和细胞治疗后癌症患者的强效体液免疫和细胞免疫。
Vaccines (Basel). 2023 Sep 15;11(9):1492. doi: 10.3390/vaccines11091492.
4
The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic.在持续的大流行中测量新冠病毒特异性T细胞反应的重要性。
Pathogens. 2023 Jun 22;12(7):862. doi: 10.3390/pathogens12070862.
5
Robust spike-specific CD4 and CD8 T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study.在接受 SARS-CoV-2 疫苗接种的造血细胞移植受者中，具有稳健的刺突特异性 CD4 和 CD8 T 细胞应答：一项前瞻性队列研究。
Front Immunol. 2023 Jul 7;14:1210899. doi: 10.3389/fimmu.2023.1210899. eCollection 2023.
6
Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis.SARS-CoV-2 疫苗免疫原性减弱与干细胞移植受者的风险因素：一项荟萃分析。
Blood Adv. 2023 Sep 26;7(18):5624-5636. doi: 10.1182/bloodadvances.2023010349.
7
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era.COVID-19 时代的异基因造血干细胞移植。
Front Immunol. 2023 Feb 22;14:1100468. doi: 10.3389/fimmu.2023.1100468. eCollection 2023.
8
SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants.患有癌症、艾滋病毒或实体器官移植的免疫功能低下个体中的SARS-CoV-2特异性T细胞反应。
Pathogens. 2023 Feb 3;12(2):244. doi: 10.3390/pathogens12020244.
9
Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.异基因造血干细胞受者接种一剂或两剂 COVID-19 疫苗加强针后强烈的 SARS-CoV-2 T 细胞反应。
Cells. 2022 Sep 27;11(19):3010. doi: 10.3390/cells11193010.
10
SARS-CoV-2 in immunocompromised individuals.免疫功能低下个体中的 SARS-CoV-2。
Immunity. 2022 Oct 11;55(10):1779-1798. doi: 10.1016/j.immuni.2022.09.006. Epub 2022 Sep 13.

本文引用的文献

1
Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant.异基因造血干细胞移植受者接种 1 剂和 2 剂 BNT162b2 mRNA 疫苗后的安全性和抗体反应。
JAMA Netw Open. 2021 Sep 1;4(9):e2126344. doi: 10.1001/jamanetworkopen.2021.26344.
2
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.血液系统恶性肿瘤患者对SARS-CoV-2疫苗的抗体反应。
Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22.
3
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.异基因造血干细胞移植受者第二次接种BNT162b2后的抗体反应。
Lancet. 2021 Jul 24;398(10297):298-299. doi: 10.1016/S0140-6736(21)01594-4. Epub 2021 Jul 13.
4
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer.mRNA 疫苗在癌症患者中的免疫原性。
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2. doi: 10.1016/j.ccell.2021.06.009. Epub 2021 Jun 18.
5
Seroconversion rates following COVID-19 vaccination among patients with cancer.癌症患者接种 COVID-19 疫苗后的血清转化率。
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.
6
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.一剂 BNT162b2 mRNA 疫苗可诱导慢性髓性白血病患者产生针对严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）的中和抗体和多功能 T 细胞反应。
Br J Haematol. 2021 Sep;194(6):999-1006. doi: 10.1111/bjh.17568. Epub 2021 Jun 3.
7
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.造血干细胞移植受者 COVID-19 的临床特征和结局：一项观察性队列研究。
Lancet Haematol. 2021 Mar;8(3):e185-e193. doi: 10.1016/S2352-3026(20)30429-4. Epub 2021 Jan 19.
8
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.人类感染 SARS-CoV-2 后三个月内中和抗体反应的纵向观察和下降。
Nat Microbiol. 2020 Dec;5(12):1598-1607. doi: 10.1038/s41564-020-00813-8. Epub 2020 Oct 26.
9
COVID-19 and Cancer: Current Challenges and Perspectives.新型冠状病毒肺炎与癌症：当前挑战与展望。
Cancer Cell. 2020 Nov 9;38(5):629-646. doi: 10.1016/j.ccell.2020.09.018. Epub 2020 Oct 1.
10
Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19.在 COVID-19 之后，英国康复个体中 SARS-CoV-2 诱导产生的广泛而强大的记忆性 CD4 和 CD8 T 细胞。
Nat Immunol. 2020 Nov;21(11):1336-1345. doi: 10.1038/s41590-020-0782-6. Epub 2020 Sep 4.

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.

作者信息

Harrington Patrick, Doores Katie J, Saha Chandan, Saunders Jamie, Child Fiona, Dillon Richard, Saglam Sukran, Raj Kavita, McLornan Donal, Avenoso Daniele, Kordasti Shahram, O'Reilly Amy, Espehana Andreas, Lechmere Thomas, Khan Hataf, Malim Michael H, Harrison Claire, Mehra Varun, de Lavallade Hugues

机构信息

Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Science, King's College London, London, UK.

Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.

出版信息

Cancer Cell. 2021 Nov 8;39(11):1448-1449. doi: 10.1016/j.ccell.2021.10.002. Epub 2021 Oct 12.

DOI:10.1016/j.ccell.2021.10.002
PMID:34717827
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8506143/
Abstract
摘要